Printer Friendly

United Kingdom : Frost & Sullivan Honours Acino Pharma for Pioneering Best Practices in the Pharmaceutical Drug Delivery Space.

Based on its recent analysis of the pharmaceutical drug delivery industry, Frost & Sullivan recognizes Acino Pharma AG with the 2014 Europe Frost & Sullivan Award for Enabling Technology Leadership. Acino s expertise in targeted drug release profiles and strong technical know-how in pellet-coating, transdermal therapeutic patches and biodegradable implants has made it the preferred vendor in contract manufacturing. It has also exhibited considerable skill in developing and manufacturing difficult to produce solid oral dosage forms and transdermal systems.

Acino s products tick the top five purchase factors of highest efficacy, Swiss quality standards, well-proven active ingredients, advanced drug delivery formulations and enhanced quality of lives for patients. Beyond that it is one of the very few global pharmaceutical companies with a comprehensive product portfolio in the malaria therapeutic segment, leveraging therapies that have been in existence over 20 years. Furthermore, it caters to the diverse requirements of local populations from endemic countries as well as those travelling to infected countries.

Acino has extensive experience with pellet-based systems, wherein free-flowing pellets can be filled into capsules or alternatively, combined with suitable excipients and pressed into tablets to form multiple unit particulate systems (MUPS) tablets. Its innovative technologies have also enabled the creation of rapidly dissolving oral disintegrating tablets (ODTs) and pellets in stick packs.

The company employs active pharmaceutical ingredients such as oxycodone and metoprolol to form innovative MUPS for supply to leading European generic companies, said Frost & Sullivan Senior Research Analyst Aiswariya Chidambaram. The oral dispersible forms are also suited for active ingredients with a high first-pass effect and facilitate the rapid onset of action because of their quick dissolution

Meanwhile, Acino s transdermal and topical therapeutic patches ensure prolonged, systemic blood levels of active pharmaceutical ingredients. Its patches are specially designed, fabricated with multiple layers including a backing film, one or more drug incorporating layers (the adhesive system) and a release liner, which is removed before application. In Europe, Acino is the second largest manufacturer of transdermal systems.

Acino also has distinct biodegradable subcutaneous drug implants that facilitate reliable, extended release of the drug over a period of one to six months, minimising the burst phenomenon. Its success in developing, manufacturing and filing transdermal patches and biodegradable implants can be amongst others be attributed to its intelligent selection of suitable materials (films, polymers, absorption enhancers) to optimise formulations.

2014 Al Bawaba ( Provided by SyndiGate Media Inc. ( ).

COPYRIGHT 2014 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Date:Nov 7, 2014
Previous Article:France : Red Hat and Wipro Extend Partnership, Collaborate to Advance Enterprise OpenStack Implementations, Deliver DevOps Solutions with OpenShift.
Next Article:United Kingdom : Appointment of Chief Executive of the Oil and Gas Authority.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters